Recently, the Department of Science and Technology of Guangdong Province announced the list of proposed Guangdong Provincial Engineering Technology Research Centers for 2023. Guangzhou Canton Biologics Technology Co., Ltd.'s "Guangdong Provincial Biologic Drug R&D and Manufacturing Service Engineering Technology Research Center" successfully passed the accreditation, thanks to its multi‑dimensional strengths including strong innovation capability, high R&D investment, excellent ability to commercialize scientific and technological achievements, and a highly skilled talent team.

The Guangdong Provincial Engineering Technology Research Center is accredited by the Department of Science and Technology of Guangdong Province and is an important part of the province's innovation system. The center is primarily established within technology‑based enterprises that demonstrate strong innovation capability and comprehensive strength in their respective industries and fields, aiming to enhance the core competitiveness and sustainable development capacity of advantageous industries, cultivate high‑tech industries, and promote industrial restructuring, upgrading, and sustainable economic and social development.

As an internationally leading biologics CDMO company, Canton Biologics has built R&D, manufacturing, and clinical supply bases in Guangzhou, Foshan, Shanghai, and Berlin, Germany. Operating with an international perspective, the company provides professional and efficient services to global partners.

In recent years, Canton Biologics has maintained strong development momentum, with continued growth in market share.
As a leading biologics CDMSO enterprise in the Guangdong‑Hong Kong‑Macao Greater Bay Area, Canton Biologics adheres to a service model of "driving business with technical capabilities," providing innovative drug companies with one‑stop CMC development, drug substance manufacturing and drug product filling, clinical supply and testing services, and has earned wide recognition from clients. Its service scope has expanded to include antibodies, fusion proteins, recombinant proteins, vaccines, plasmids/viruses, stem cells/immune cells, and more, fully supporting the thriving development of the biopharmaceutical market.

Looking ahead, Canton Biologics will continue to uphold its high‑quality service philosophy, better leveraging its technology platforms in China and Europe to provide more efficient and flexible services for Chinese biotechnology companies going global and for overseas biotech companies entering China. The company will help clients accelerate the R&D of clinical drugs from molecule to commercial production, creating new brilliance for global biotechnological innovation and economic development.